Positioning Asenapine: A Review of Current Schizophrenia Guidelines

Course overview

Asenapine is a second-generation antipsychotic approved for the treatment of schizophrenia in adults and adolescents, and for acute manic or mixed episodes in bipolar I disorder. It is distinct for its non-oral formulations, including a sublingual tablet and transdermal patch, offering alternatives for patients with swallowing difficulties or adherence challenges. Asenapine exhibits high-affinity antagonism at dopamine D2 and serotonin 5-HT2A receptors, with minimal anticholinergic and metabolic effects. While not prioritized as a first-line agent in major guidelines, it is recognized as a second-line option for patients with extrapyramidal symptom risk or metabolic vulnerability.